Kröger H, Honkanen R, Saarikoski S, Alhava E
Department of Surgery, Kuopio University Hospital, Finland.
Ann Rheum Dis. 1994 Jan;53(1):18-23. doi: 10.1136/ard.53.1.18.
Although periarticular osteoporosis is a well-recognised phenomenon in rheumatoid arthritis (RA), there is considerable controversy over whether RA is associated with more generalised osteoporosis. The aetiology of this bone loss is probably multifactorial, including both life-style risk factors and disease-related determinants. Population-based studies on bone mineral density (BMD) in RA have not previously been conducted, and the purpose of the present cross-sectional population-based study was to determine whether patients with RA are at an increased risk of having osteoporosis. Furthermore, the determinants of BMD in RA patients were investigated.
BMD at the spine and femoral neck was measured in 143 women with RA. The control group consisted of 1611 women with no disease or taking any drugs known to affect bone metabolism. The study population was a random stratified sample from the Kuopio Osteoporosis Study, which included all perimenopausal women aged 47-56 years residing in Kuopio Province, Eastern Finland in 1989 (n = 14,220). The mean age of the patients at the time of densitometry was 53.7 years.
The mean (SD) spinal and femoral neck BMD was significantly lower in patients with RA compared with controls [spine: 1.067 (0.161) v 1.129 (0.157) g/cm2, p < 0.001; femoral neck: 0.851 (0.136) v 0.932 (0.123) g/cm2, p < 0.001]. Analysis of variance showed that at the spine the difference was significant only in patients having corticosteroid treatment, whereas at the femoral neck patients with non-steroid treatment also had significantly lower BMD. When confounding factors were corrected, no significant difference could be found between non-steroid and corticosteroid treated patients with RA, suggesting that the independent effect of corticosteroids on BMD is only minimal. Multiple regression analysis found age, weight and functional grade to be significant predictors of spinal BMD (R2 = 0.403, p < 0.001). In the femoral neck weight, cumulative corticosteroid dose and functional grade were significant predictors of BMD (R2 = 0.410, p < 0.001).
RA is associated with generalised osteoporosis. The physical impairment and body weight are the major determinants of both spinal and femoral bone mass in RA patients. The cumulative corticosteroid dose was also a significant determinant of femoral neck BMD. However, the independent effect of corticosteroids is questionable because the use of corticosteroids may be an indicator of more severe disease.
虽然关节周围骨质疏松是类风湿关节炎(RA)中一种广为人知的现象,但对于RA是否与更广泛的骨质疏松相关仍存在相当大的争议。这种骨质流失的病因可能是多因素的,包括生活方式风险因素和疾病相关决定因素。此前尚未开展基于人群的RA骨密度(BMD)研究,本项基于人群的横断面研究旨在确定RA患者患骨质疏松症的风险是否增加。此外,还对RA患者BMD的决定因素进行了调查。
对143名RA女性患者测量其脊柱和股骨颈的BMD。对照组由1611名无疾病或未服用任何已知会影响骨代谢药物的女性组成。研究人群是来自库奥皮奥骨质疏松研究的随机分层样本,该研究纳入了1989年居住在芬兰东部库奥皮奥省的所有47 - 56岁围绝经期女性(n = 14220)。进行骨密度测量时患者的平均年龄为53.7岁。
与对照组相比,RA患者的脊柱和股骨颈平均(标准差)BMD显著更低[脊柱:1.067(0.161)对1.129(0.157)g/cm²,p < 0.001;股骨颈:0.851(0.136)对0.932(0.123)g/cm²,p < 0.001]。方差分析表明,在脊柱部位,差异仅在接受皮质类固醇治疗的患者中显著,而在股骨颈部位,接受非甾体治疗的患者BMD也显著更低。校正混杂因素后,接受非甾体和皮质类固醇治疗的RA患者之间未发现显著差异,这表明皮质类固醇对BMD的独立作用极小。多元回归分析发现年龄、体重和功能分级是脊柱BMD的显著预测因素(R² = 0.403,p < 0.001)。在股骨颈部位,体重、累积皮质类固醇剂量和功能分级是BMD的显著预测因素(R² = 0.410,p < 0.001)。
RA与全身性骨质疏松相关。身体损伤和体重是RA患者脊柱和股骨骨量 的主要决定因素。累积皮质类固醇剂量也是股骨颈BMD的显著决定因素。然而,皮质类固醇 的独立作用存在疑问,因为使用皮质类固醇可能是疾病更严重的一个指标。